|
DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
16.02.2022 / 08:30
The issuer is solely responsible for the content of this announcement.
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER
Vancouver, BC, Canada, February 16th, 2022 - Defence Therapeutics Inc. ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the establishment of an agreement with Cato SMS, to advise on the submission of its clinical application to Health Canada in order to initiate a Phase I trial using AccuTOXTM against breast cancer.
CATO SMS is a consulting firm with more than 30 years of global experience to guide clinical development of biopharma pipelines. With offices across North America, Europe, and the Middle East, CATO SMS has experience conducting trial designs in more than 25 countries. Their specialists deliver innovative regulatory consulting solutions to guide complex challenges with a proven center of excellence in oncology.
"We are very pleased to work with Cato SMS on our AccuTOXTM program. This step is central to Defence as it ensures the achievement of important milestones for our clinical program. Cato SMS will be designing the clinical protocol, pre-CTA meeting package, CTA Compilation and Submission as well as regulatory affairs for our AccuTOXTM Phase I trial" says Mr. Plouffe, the CEO of Defence.
The AccuTOXTM program consists of using a lead variant of the AccumTM molecule to trigger cell death in cancer cells. When combined with the immune-checkpoint inhibitor CTLA-4, this lead AccumTM triggered potent anti-tumoral response in several cancer models including, T-cell lymphoma, melanoma, colon and breast cancer. As such, Defence plans to use AccuTOXTM in its Phase I to treat breast cancer patients in Q4 of 2022.
According to Fortune Business InsightsTM, the Global Breast Cancer Therapeutics Market to exhibit 13.1% CAGR and hit USD 55.27 Billion till 2027.
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
16.02.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
